Insider Buying: Elanco Animal Health (NYSE:ELAN) Insider Buys $99,938.85 in Stock

Elanco Animal Health Incorporated (NYSE:ELAN) insider Rajeev Modi bought 4,911 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was purchased at an average price of $20.35 per share, with a total value of $99,938.85. Following the completion of the acquisition, the insider owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Elanco Animal Health Stock Performance

Shares of ELAN opened at $21.31 on Friday. Elanco Animal Health Incorporated has a one year low of $12.40 and a one year high of $27.72. The company has a 50-day moving average of $23.05 and a two-hundred day moving average of $23.29. The stock has a market cap of $10.64 billion, a price-to-earnings ratio of -42.61, a PEG ratio of 2.24 and a beta of 1.69. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.16 and a quick ratio of 1.12.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The company had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.28 billion. During the same period last year, the company posted $0.37 earnings per share. The business’s revenue for the quarter was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, equities research analysts expect that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Wall Street Zen upgraded shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 16th. Weiss Ratings cut shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. Citigroup raised their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Piper Sandler upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $24.00 to $30.00 in a report on Thursday, January 22nd. Finally, UBS Group restated a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $28.20.

Institutional Trading of Elanco Animal Health

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Elanco Animal Health by 1.6% during the third quarter. Vanguard Group Inc. now owns 48,586,708 shares of the company’s stock worth $978,536,000 after purchasing an additional 759,623 shares during the period. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Elanco Animal Health by 11.8% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock worth $797,197,000 after purchasing an additional 3,717,404 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Elanco Animal Health by 1.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 25,082,545 shares of the company’s stock worth $567,622,000 after purchasing an additional 373,869 shares during the period. UBS Group AG boosted its holdings in shares of Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after purchasing an additional 5,961,457 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Elanco Animal Health by 7.3% in the fourth quarter. Geode Capital Management LLC now owns 9,425,533 shares of the company’s stock valued at $213,343,000 after acquiring an additional 640,098 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.